After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...

Swiss pharmaceutical company Roche has announced that a new antibiotic, zosurabalpin, is progressing to phase 3 testing.

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Outset Ventures, the Auckland-based venture firm and incubator that spun out deep tech unicorns like Rocket Lab and LanzaTech ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Zealand Pharma. “He joins Zealand at a key moment as we embark on the collaboration with Roche to co-develop and co-commercialize petrelintide as a foundational therapy for people with overweight and ...

Zealand Pharma A/S is a leading non-Big Pharma player in obesity drugs, with a promising pipeline and a major partnership with Roche for petrelintide. Petrelintide, an amylin analog, could rival ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma Twenty-nine patients were enrolled. The ORR was ...